Clinical Trial Update: Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating calprotectin-directed maintenance therapy with Humira (adalimumab) for Crohn's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: Peter Higgins | Conditions: Crohn's Disease | Phase 3 | Status: WITHDRAWN